StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.14+0.04 (+0.17%)

Close on Nov 18, 2026Market cap $463.06MP/E –Yield –

Neurogene revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Neurogene's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$925.00K–
FY2023Dec 31, 2023$0-100.0%
FY2018Dec 31, 2018$25.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$925.00K–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$25.00M–

More Neurogene figures

See a number that looks wrong?